Clinical Trial Update: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports that GI Innovation is studying GI-101 and GI-101A as single agents or in combination with pembrolizumab or lenvatinib in Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Clear Cell Renal Cell Carcinoma
• Solid Tumors
• Squamous Cell Non-small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• GI-101 (GI-101)
• GI-101A (GI-101A)

Snippet

Sponsor: GI Innovation, Inc. | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING